Abstract
α-Hemoglobin fragments α-(133-141), α-(134-141), α-(135-141), α-(137-141), α-(134-140), α- (133-138), α-(134-140) and α-(137-138) stimulate L929 tumor cell proliferation, α-(134-141) being the most active. α-(134-141) stimulates proliferation of M3 melanoma cells, murine embryonic fibroblasts, primary cultures of red bone marrow and spleen cells. In L929 cells the effect of α-(134-141) is cell density independent; in M3 cells α-(137-141) and α-(134-141) are most active at density 10,000 cells / well (96 well plate) independently on FBS content.
Keywords: neokyotorphin, proliferation
Protein & Peptide Letters
Title: Proliferative Activity Of Neokyotorphinrelated Hemoglobin Fragments In Cell Cultures
Volume: 10 Issue: 4
Author(s): Olga V. Sazonova, Elena Yu. Blishchenko, Olga A. Kalinina, Natalya S. Egorova, Andrei Yu. Surovoy, Marina M. Philippova, Andrei A. Karelin and Vadim T. Ivanov
Affiliation:
Keywords: neokyotorphin, proliferation
Abstract: α-Hemoglobin fragments α-(133-141), α-(134-141), α-(135-141), α-(137-141), α-(134-140), α- (133-138), α-(134-140) and α-(137-138) stimulate L929 tumor cell proliferation, α-(134-141) being the most active. α-(134-141) stimulates proliferation of M3 melanoma cells, murine embryonic fibroblasts, primary cultures of red bone marrow and spleen cells. In L929 cells the effect of α-(134-141) is cell density independent; in M3 cells α-(137-141) and α-(134-141) are most active at density 10,000 cells / well (96 well plate) independently on FBS content.
Export Options
About this article
Cite this article as:
Sazonova V. Olga, Blishchenko Yu. Elena, Kalinina A. Olga, Egorova S. Natalya, Surovoy Yu. Andrei, Philippova M. Marina, Karelin A. Andrei and Ivanov T. Vadim, Proliferative Activity Of Neokyotorphinrelated Hemoglobin Fragments In Cell Cultures, Protein & Peptide Letters 2003; 10 (4) . https://dx.doi.org/10.2174/0929866033478780
DOI https://dx.doi.org/10.2174/0929866033478780 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Current Drug Targets The Adenine Nucleotide Translocator: A New Potential Chemotherapeutic Target
Current Drug Targets New Anti-Mitotic Drugs with Distinct Anti-Calmodulin Activity
Mini-Reviews in Medicinal Chemistry Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Non-Invasive Cell Tracking in Cancer and Cancer Therapy
Current Topics in Medicinal Chemistry The Emerging Role of MicroRNA in Schizophrenia
CNS & Neurological Disorders - Drug Targets Rapid Estrogen Signaling in Spermatogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Drug Targeting Strategies in Cancer Treatment: An Overview
Mini-Reviews in Medicinal Chemistry The Role of Foxp3 in Regulatory T Cell Differentiation and Function
Current Immunology Reviews (Discontinued) Antioxidant Supplementation on Cancer Risk and During Cancer Therapy: An Update
Current Topics in Medicinal Chemistry New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Non Polymeric Nanoparticles for Photodynamic Therapy Applications: Recent Developments
Current Medicinal Chemistry Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery Novel Mitotic Targets and Their Small-Molecule Inhibitors
Current Cancer Drug Targets From Systems Biology to Systems Pathology: A New Subspecialty in Diagnostic and Personalized Medicine
Current Pharmacogenomics and Personalized Medicine From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design AMPK As A Target in Rare Diseases
Current Drug Targets Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design